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Abstract
Background: The present study aims to identify antigens in protein extracts of promastigote and amastigote-like
Leishmania (Leishmania) chagasi syn. L. (L.) infantum recognized by antibodies present in the sera of dogs with asymptomatic
and symptomatic visceral leishmaniasis (VL).
Methodology/Principal Findings: Proteins recognized by sera samples were separated by two-dimensional electrophoresis
(2DE) and identified by mass spectrometry. A total of 550 spots were observed in the 2DE gels, and approximately 104
proteins were identified. Several stage-specific proteins could be identified by either or both classes of sera, including, as
expected, previously known proteins identified as diagnosis, virulence factors, drug targets, or vaccine candidates. Three,
seven, and five hypothetical proteins could be identified in promastigote antigenic extracts; while two, eleven, and three
hypothetical proteins could be identified in amastigote-like antigenic extracts by asymptomatic and symptomatic sera, as
well as a combination of both, respectively.
Conclusions/Significance: The present study represents a significant contribution not only in identifying stage-specific L.
infantum molecules, but also in revealing the expression of a large number of hypothetical proteins. Moreover, when
combined, the identified proteins constitute a significant source of information for the improvement of diagnostic tools
and/or vaccine development to VL.
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Introduction
Visceral leishmaniasis (VL) is an important parasitic disease,
with a worldwide distribution in 88 countries, where a total of 350
million people may be at risk. In Brazil, the disease is an endemic
zoonosis caused by the parasitic protozoa Leishmania (Leishmania)
chagasi syn. L. (L.) infantum [1]. Dogs are the main parasite domestic
reservoirs, and culling of seropositive dogs, as detected by means of
serological tests using promastigote antigens, i.e. RIFI or ELISA, is
a major VL control measure adopted in Brazil. Therefore, to
reduce the transmission of parasites between dogs and humans, it
is necessary, among other aspects, to diagnose canine visceral
leishmaniasis (CVL) as early as possible, by means of sensitive and
specific diagnostic tools [2,3].
Upon infection, dogs develop three different stages of the
disease: symptomatic, oligosymptomatic, and asymptomatic [4].
Symptomatic infections tend to evolve into animal deaths, and
their clinical manifestations include cutaneous alterations, such as
alopecia, dermatitis, and onychogryphosis [5,6], as well as visceral
dysfunctions in the kidneys, liver, and heart [7,8]. A high number
of infected dogs remain asymptomatic and present low levels of
specific antibodies; however, some dogs do in fact develop a few
mild symptoms, which are classified as oligosymptomatic [4].
Routine diagnosis of leishmaniasis has been based on classic
parasitological methods, where infected skin tissue and aspirates,
or biopsy specimens of visceral tissues (i.e., spleen, liver, and bone
marrow), undergo microscopic examinations and cultures [9].
Classic serological methods are limited by low sensitivity and/or
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specificity of the tests, requiring repeated tissue sampling and a trained
laboratory staff [10]. The diagnosis of CVL, by means of ELISA,
based on Leishmania antigens has shown variable values of sensitivity
and/or specificity, mainly due to antigenic similarities between
Leishmania and other protozoa [10]. As a strategy to develop a more
specific test, several parasite antigens have been tested in prior studies
[11–14]; however, due to frequent low specificity and sensitivity in
detecting asymptomatic infections and the high variability observed in
the humoral response of individual infected dogs [15], it has been
postulated that an efficient diagnosis may require a mixture of antigens
or the use of chimerical antigens [16–19].
Proteomic approaches applied to study Leishmania protein
expression patterns offer the possibility to assign potential func-
tions for proteins, including those previously identified by geno-
mics as hypothetical, new diagnostic markers, vaccine candidates,
and/or potential drug targets [20–23]. Several proteomic studies
have been performed to study stage-specific expression and
differentiation in Leishmania [24–32]. The coupling of antibodies
specific to parasite antigens generated during different stages of
disease progression in dogs will certainly contribute to refining this
analysis, which aims to identify not only differentially expressed
proteins, but also potentially new antigens identified by the
immune system during active infection. Recently, the discovery of
antigens through proteomics has been indicated as one of the main
research priorities for further development and improvement of
leishmaniasis vaccines [33].
In this work, an immunoproteomic approach, together with
two-dimensional electrophoresis (2DE) and mass spectrometry, was
carried out to analyze the protein expression profiles of promasti-
gote and amastigote-like L. infantum. Aimed at identifying new
diagnostic markers and/or vaccine candidates, antibodies present in
the sera of dogs with asymptomatic and symptomatic VL were
added to this analysis, allowing for the identification of several
known, as well as hypothetical, L. infantum antigenic proteins.
Materials and Methods
Parasite culture
Experiments were carried out using the Leishmania (Leishmania)
chagasi syn. L. (L.) infantum (MHOM/BR/1970/BH46) strain. The
stationary phase of promastigote cells were grown at 24uC in
Schneider’s medium (Sigma, St. Louis, MO, USA), supplemented
with 20% inactivated fetal bovine serum (FBS, Sigma), 20 mM L-
glutamine, 200 U/mL penicillin, and 100 mg/mL streptomycin, at
pH 7.2, as previously described [34]. The amastigote-like cells
were obtained as described by Doyle et al. (1991) [35].
Sera samples
The present study used sera samples from 60 L. infantum-infected
dogs (40 clinically symptomatic and 20 asymptomatic) from Belo
Horizonte, Minas Gerais, Brazil. Animals were considered sym-
ptomatic when three or more of the following symptoms were
present: loss of weight, hepatomegaly, alopecia, adenopathy,
onychogryposis, conjunctivitis, and exfoliative dermatitis on the
nose, tail, or ear tips. The asymptomatic animals were free from
clinical symptoms. All sera samples from either symptomatic or
asymptomatic animals were positive when tested by RIFI and
ELISA, and the presence of amastigote stage of the parasite was
confirmed by microscopic observation and in vitro culture using
aspirates from popliteal and/or prescapular lymphoid nodes or
bone marrow and/or tissue fragments. The control group
consisted of sera from 20 dogs living in non-endemic areas from
VL, with no clinical signs or suspicion of leishmaniasis, and which
showed negative parasitological and serological tests. Sera samples
used in this study were kindly provided by Dr. Maria Norma Melo
(Departmento de Parasitologia, Instituto de Cieˆncias Biolo´gicas,
UFMG).
Preparation of protein extracts
The protein extraction from promastigote and amastigote-like
stages L. infantum and 2DE were performed following a modified
protocol [36]. Briefly, cells from both stages (161010 cells) were
washed three times in 40 mM Tris-HCl, pH 7.2, by centrifu-
gation at 50006 g for 10 min at 4uC. The pellets were
resuspended in lyses buffer solution [7 M urea, 2 M thiourea,
4% chol-amidopropyl dimethylammonio-1-propanesulfonate
(CHAPS), 40 mM dithiothreitol (DTT), 2% IPG buffer
(pH 4–7), 40 mM Tris], and a protease inhibitor cocktail (GE
Healthcare, Upsala, Sweden) was added. Samples were
incubated for 1 h at room temperature, with occasional
vortexing. Purification was carried out by protein precipitation
using a 2D Clean UpKit (GE Healthcare), according to
manufacturer instructions. Whole cell extracts were measured
by a 2D Quant-Kit (GE Healthcare), and aliquots were
immediately frozen at 280uC, until use.
Isoeletric focusing (IEF)
For the first-dimension electrophoresis, 150 mg of protein
extract was added to a volume of 250 mL with a rehydration
solution [7 M urea, 2 M thiourea, 2% CHAPS, 40 mM DTT, 2%
immobilized pH gradient (IPG-buffer, pH 4–7, trace bromophe-
nol blue)]. Next, samples were applied to IPG strips (13 cm, pH 4–
7; GE Healthcare) for passive rehydration overnight at room
temperature. After in-gel rehydration for 12 h, isoeletric focusing
was performed at 500 V for 1 h, 1.000 V for 1 h, and 8.000 V for
8 h, using a Multiphor II electrophoresis unit and EPS 3500 XL
power supply (Amersham, Piscataway, NJ, USA).
SDS-PAGE
After IEF, each strip was incubated for 15 min in a solution
made up of 10 mL of a 50 mM Tris-HCl buffer pH 8.8, 6 M
urea, 30% (v/v) glycerol, 2% (w/v) SDS, 0.002% bromophenol-
blue, and 125 mM DTT, followed by a second incubation step in
Author Summary
Canine visceral leishmaniasis (CVL) is an important
emerging zoonosis caused by Leishmania (Leishmania)
infantum in the Mediterranean and Middle East and L. (L.)
chagasi (syn. L. (L.) infantum) in Latin America. Due to their
genotypic relationships, these species are considered iden-
tical. The present study focused on comparing the protein
expression profiles of the promastigote and amastigote-like
stages of L. infantum, by means of a protein separation by
two-dimensional electrophoresis and identification by mass
spectrometry. The present study attempted to identify
proteins recognized by antibodies present in the sera of
dogs with asymptomatic and symptomatic visceral leish-
maniasis. A total of one hundred and four proteins were
identified. Of these, several stage-specific proteins had been
previously identified as diagnosis and/or vaccine candi-
dates. In addition, antibodies from infected dogs recognized
thirty-one proteins, which had been previously considered
hypothetical, indicating that these proteins are expressed
during active infection. Therefore, the present study reveals
new potential candidates for the improvement of diagnosis
of CVL.
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the same buffer solution, excluding DTT, which was replaced by
125 mM iodacetamide. IPG strips were transferred to a 12%
polyacrilamide and sealed with agarose solution (agarose and
bromophenol blue in a Tris-glicine cathode buffer). The protein
standard was purchased from Invitrogen (BenchMark Protein
Ladder). Electrophoresis was performed in a Mini-Protean II
system (BioRad) connected to a MultiTemp II cooling bath
(Amersham Biosciences), in a Tris/glycine/SDS buffer. Proteins
were separated at 200 V, until the dye front had reached the
bottom of the gel.
Immunoblotting 2DE analysis and protein identification
To identify the reactive spots that were recognized by the
antibodies present in the sera samples from asymptomatic and/or
symptomatic CVL, Western blot analyses were performed. Whole
cell extracts of promastigote and amastigote-like L. infantum were
separated electrophoretically and transferred onto cellulose
membranes (Schleicher & Schull, Dassel, Germany) by semi-dry
blotting for 2 h at 400 mA. Membranes were blocked in 5% (w/v)
low-fat dried milk in TBS 16 (pH 7.4) plus 0.05% Tween 20 for
2 h at room temperature. Next, the membranes were washed 6
times (10 min each) with the blocking solution and pre-incubated
in a pool of sera of symptomatic or asymptomatic CVL (1:200
diluted) for 2 h at room temperature. Then, membranes were
incubated with a peroxidase-conjugated goat anti-dog IgG
secondary antibody (1:5.000 diluted) for 2 h at room temperature.
After having been washed 3 times with TBS 16plus 0.5% Tween
20, immunoblots were developed, using a solution made up of
chloronaphtol, diaminobenzidine and H2O2. To select and
identify the spots recognized by antibodies of CVL sera, three
independent protein preparations, each obtained from indepen-
dent parasite cultures, were performed. The 2DE gels were stained
with colloidal Coomassie Brilliant Blue G-250, following proce-
dures described by Neuhoff et al. (1988) [37]. For image analysis,
the stained gels were scanned using an ImageScanner III (GE
Healthcare). Reactive spots recognized by antibodies in the sera
samples of asymptomatic and/or symptomatic CVL were excised
manually from the gels for protein identification.
Protein digestion, peptide extraction, and spot handling
Spots were manually excised, and fragments were washed in
25 mM ammonium bicarbonate/50% acetonitrile until complete-
ly destained. After drying, gel fragments were placed on ice in a
50 mL protease solution (20 ng/mL of a sequence grade-modified
trypsin in a 25 mM ammonium bicarbonate) (Promega Biosci-
ences, CA, USA), for 30 min. Excess protease solution was
removed and replaced by 25 mM ammonium bicarbonate.
Digestion was performed at 37uC for 18 h. Peptide extraction
was performed twice for 15 min, using 30 mL of 50% acetonitrile/
5% formic acid. Trypsin (Promega) digests were concentrated in a
Speed-Vac (Savant, USA) to approximately 10 mL and desalted
using Zip-Tip (C18 resin; P10, Millipore Corporation, Bedford,
MA, USA). Samples were mixed with a matrix (5 mg/ml
recrystallized a-cyano-4-hydroxycinnamic acid) in a volume of
1 mL (1:1 ratio) and then spotted for MALDI-TOF/TOF
Ultraflex III (Bruker, Daltonics, Germany).
Protein identification and database search
To determine the MS spectrum of the immunoreactive spots,
the digests were spotted onto 600 mm Anchorchips (Bruker
Daltonics). Spotting was achieved by pipetting, in duplicate,
1 mL of analyte onto the MALDI target plate, then adding 5 mg/
mL a-cyano-4-hydroxycinnamic acid diluted in 3% TFA/50%
acetonitrile, which contained 2 mM ammonium phosphate. The
Bruker peptide calibration mixture was spotted down for external
calibration. All samples were allowed to air dry at room tem-
perature, and 0.1% TFA was used for on-target washing. All
samples were analyzed in the positive-ion, reflection mode, through
a MALDI-TOF/TOF Ultraflex III mass spectrometer (Bruker,
Daltonics, Germany). Each spectrum was produced by accumulat-
ing data from 200 consecutive laser shots, with a frequency of
100 Hz, and an m/z range of 1.000–4.000. Instrument calibration
was achieved by using peptide calibration standard II (Bruker
Daltonics), a mixture of angiotensin I & II, substance P, bombesin,
ACTH clip 1–17, ACTH clip 18–39 and somatostatin 28, as the
internal standard. Peptide masses were measured as mono-isotopic
masses. The MS peaks with the highest intensities were selected for
MS/MS fragmentation analyses.
The resulting spectra were processed using Flex analysis
software, version 2.4 (Bruker Daltonics), with the following settings:
peak detection algorithm set at SNAP (Sort Neaten Assign and
Place), S/N threshold at 3, precursor and product ion tolerances
were set at 0.5 Da, and quality factor threshold at 50. The
trypsin autodigestion ion peaks (842.51, 1045.56, 2211.10, and
2225.12 Da) were used as internal standards to validate the external
calibration procedure. Matrix, and/or autoproteolytic trypsin
fragments, and known contaminants (i.e., keratins) were manually
removed. The resulting peptides list was used to search in the NCBI
database (http://blast.ncbi.nlm.nih.gov) for the organism option of
Leishmania (taxid:5658). According to the obtained results, and using
the peptide sequences identified for each protein, the following
parameters were used as selection criteria: total score, query
coverage, and E value. Poor quality spectra were not considered for
selection in the protein sequence database.
Results
2DE protein maps of promastigote and amastigote-like
total extracts of Leishmania infantum
Electrofocusing on pH 4–7 IPG strips, approximately 350 protein
spots in L. infantum promastigote and 200 spots in amastigote-like
stages could be observed clearly (Figure 1). Promastigote stages, as
compared to amastigote-like forms, presented a larger number of
visible spots, and differences could be observed in the molecular
weights of the band profiles obtained between them: most of the
promastigote spots were found between 15 and 50 kDa (Figure 1A),
while in the amastigote-like stage, these bands tended to be
distributed between 25 and 70 kDa (Figure 1B). The 2DE spot
profiles obtained from promastigote and amastigote-like were highly
reproducible in terms of both the total number of protein spots and
their relative positions and intensities in the three 2DE gels
performed in this study (data not shown).
Immunoblotting analysis of 2DE maps of promastigote
and amastigote-like stages of Leishmania infantum
To investigate the antigenicity of proteins in the L. infantum
promastigote stage, immunoblots were performed, using a pool of
symptomatic and asymptomatic VL dogs’ sera. Using the profile
obtained from the 2DE gel as a comparison (Figure 2A), the pool
of sera from asymptomatic VL dogs reacted by presenting approx-
imately 40 protein spots in the promastigote extract (Figure 2B),
whereas when the pool of sera from symptomatic VL dogs were
used, the immunoblots revealed approximately 80 protein spots
(Figure 2C).
In this same manner, using the 2DE gel profile obtained of
amastigote-like extract for comparison (Figure 3A), the sera of
asymptomatic VL dogs reacted by presenting approximately 30
protein spots (Figure 3B), whereas when the sera from VL symptomatic
Immunoproteomic Approach in Leshmania infantum
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dogs were used, immunoblots revealed approximately 70 protein spots
(Figure 3C). It is important to note that how a pool of sera of
symptomatic (n = 40) or asymptomatic (n = 20) VL dogs was used in
the experiments, the individual variability in the humoral responses did
not bias the reactivity observed in the immunoblotting analysis. As
a control, the different 2DE gels and immunoblots applied to
promastigote and amastigote-like extracts were probed with sera of
control dogs presenting negative parasitological, clinical, and serolog-
ical analyses, and no protein spot could be detected in either case (data
not shown).
In Figure 4, the diagram shows that, from a total of 104 (100%)
proteins in both promastigote and amastigote-like extracts, 64
(62%) could be identified by the sera of symptomatic CVL, while
the sera of asymptomatic animals detected that 19 (18%) and 21
(20%) proteins proved to be reactive in both classes of sera,
respectively. Of the proteins identified in promastigote antigenic
extracts, the sera of symptomatic and asymptomatic VL dogs, as
well as the combination of both sera, could identify approximately
49%, 20%, and 31% of the proteins, respectively. In amastigote-
like extract, the sera of asymptomatic and symptomatic VL
Figure 1. Two-dimensional profiles of the total extracts from Leishmania infantum promastigote and amastigote-like stages. 2DE gels
were obtained after separation of promastigote (in A) and amastigote-like (in B) protein extracts (150 mg, each one) by 2DE (first dimension: IEF pH
range 4–7, second dimension: 12% SDS-PAGE), and staining with colloidal Coomassie Brilliant Blue G-250. 2DE gels were derived from three
independent protein preparations. One representative preparation of each parasite stage was used in this study.
doi:10.1371/journal.pntd.0001430.g001
Figure 2. Immunoproteomic analyses of the protein extract from the Leishmania infantum promastigote stage. 2DE gels obtained after
separation of total protein extract (150 mg) of promastigote stage by 2DE (first dimension: IEF pH range 4–7, second dimension: 12% SDS-PAGE), and
staining with colloidal Coomassie Brilliant Blue G-250 (A, as described in Figure 1). Immunoblots of reactive spots were identified after incubation of
the membrane with pools of sera of asymptomatic (B) or symptomatic (C) VL dogs. Bound antibodies were detected with goat anti-dog IgG
antibodies at a 1:5.000 dilution. The x-axis represents the tentative isoeletric point (pI), while the y-axis represents the approximate molecular weight
(kDa) as determined by a commercial 2DE gel marker (BenchMark Protein Ladder). Protein spots were numbered, and their identities are given in
Figure 5. Immunoblots are a reliable representation of three independent experiments.
doi:10.1371/journal.pntd.0001430.g002
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animals and the combination of both sera classes identified
approximately 74%, 17%, and 9% of the proteins, respectively.
Identification of Leishmania infantum promastigote
proteins by MS/MS and the use of protein databases
In an attempt to establish a reference map of identified spots
using the sera of asymptomatic and symptomatic VL dogs in
immunoblots with L. infantum promastigote stage, 51 well-identified
spots were used (25, 10, and 16 identified by symptomatic,
asymptomatic, and the combination of both sera classes,
respectively). Reactive spots were selected and excised from
2DE gels for analyses by mass spectrometry, as described in the
Materials and Methods Section. Results are summarized in
Figure 5.
Among the proteins recognized by the sera of symptomatic VL
dogs, 7 hypothetical and 18 known proteins, which included
cysteine proteinases, heat shock proteins (HSP70 and HSP83), and
other proteins related to parasite virulence, such as disulfide
isomerase [38,39], cyclophilin [40], and cytochrome c oxidase VII
[41,42] were detected. Possible targets for therapeutic interven-
tions, such as GTP-binding protein; proteins already characterized
for diagnosis, such as KMP-11 [43,44] and calreticulin [45]; and
vaccine candidates, such as KMP-11 [46] and Lcr1 protein [47],
were also observed. Using the sera of asymptomatic VL dogs, 3
hypothetical and another 7 known proteins were detected, in-
cluding a protein kinase, elongation factor (eIFE), and cythcrome
p450, which have been considered therapeutic targets for
leishmaniasis [48–51]. Five hypothetical proteins could be
identified by both sera classes, whereas among the proteins with
identifiable functions, some have been previously evaluated as
candidates for the diagnosis and/or vaccine for leishmaniasis, such
as nucleoside hydrolase [52], ribosomal proteins [53,54], perox-
idoxin [55], and b-tubulins [56,57].
Identification of Leishmania infantum amastigote-like
proteins by MS/MS and the use of protein databases
Due to the importance of the amastigote life cycle in leish-
maniasis, this parasite stage cultured in axenic conditions was
immunoblotted with the sera of asymptomatic and symptomatic
VL dogs. The analysis of approximately 200 protein spots allowed
for the identification of 53 well-defined proteins that were
recognized by the sera of asymptomatic and symptomatic CVL;
with 39, 9, and 5 identified by symptomatic, asymptomatic, and
the combination of both sera classes, respectively. Similar to the
study with promastigote stage, reactive spots were selected and
excised from 2DE gels for identification. It is worth noting that A2
[13], ATP-dependent RNA helicase [58], and amastin [59]
proteins were identified only in the amastigote-like extract, since
these proteins are characterized as amastigote-specific in Leishmania
(Figure 6).
When the sera of asymptomatic VL dogs were used against
amastigote-like stage, 2 hypothetical and 7 known proteins, in-
cluding the phosphatase 2C protein [60], virulence factors (pro-
hibitin) [61], diagnosis markers, vaccine candidates (mitochondrial
tryparedoxin peroxidase) [62], and drug targets (succinyl-coA ligase
[GDP-forming] b-chain) [63] could also be identified.
A significant number of proteins (39 of 53) were found to be
present in both stages and to react with sera of symptomatic VL
dogs. Several of these are linked to housekeeping metabolism
pathways, such as protein synthesis or cellular stress, and included
ribosomal proteins, cyclophilin, Haspb, cysteine proteinases, eIFE,
and heat shock proteins [30,53,54]. In addition, some proteins
involved in parasite virulence, such as fructose-1,6-biphosphateal-
dolase (aldolase) [64,65], as well as therapeutic targets, such as
ATPase b-subunit [66], cysteine peptidases [67], and methylthioa-
denosine phosphorylase [68], could also be identified.
Discussion
The present work applied an immunoproteomic approach in L.
infantum promastigote and amastigote-like antigenic extracts, using
pools of sera of asymptomatic and/or symptomatic VL dogs, in an
attempt to compare their protein expression profiles and identify
new targets for future immunological applications of VL. The use
of pools of sera of both asymptomatic and symptomatic VL dogs in
this study appears to have reduced the impact of individual animal
immune response variations on L. infantum antigens.
Figure 3. Immunoproteomic analyses of the protein extract from the Leishmania infantum amastigote-like stage. 2DE gels obtained
after the separation of total protein extracts (150 mg) of amastigote-like stages by 2DE (first dimension: IEF pH range 4–7, second dimension: 12%
SDS-PAGE), and staining with colloidal Coomassie Brilliant Blue G-250 (A, as described in Figure 1). Immunoblots of reactive spots were identified after
incubation of the membrane with pools of sera of asymptomatic (B) or symptomatic (C) VL dogs. Bound antibodies were detected with goat anti-dog
IgG antibodies at a 1:5.000 dilution. The x-axis represents the tentative isoeletric point (pI), while the y-axis represents the approximate molecular
weight (kDa) as determined by a commercial 2DE gel marker (BenchMark Protein Ladder). Protein spots were numbered, and their identities are listed
in Figure 6. Immunoblots are a reliable representation of three independent experiments.
doi:10.1371/journal.pntd.0001430.g003
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Figure 4. Comparison of spots identified in protein extracts from promastigote and amastigote-like stages of Leishmania infantum.
Diagrams show the percentage of protein spots identified in either individual or combined parasite stages. In A, the percentage of total proteins
identified by asymptomatic (19/18%), symptomatic (64/62%), and a combination of both sera classes (21/20%). In B, the percentage of proteins from the
promastigote stage identified by asymptomatic (10/20%), symptomatic (25/49%), and a combination of both sera classes (16/31%). In C, the percentage
of proteins from amastigote-like stage identified by asymptomatic (9/17%), symptomatic (39/74%), and a combination of both sera classes (5/9%).
doi:10.1371/journal.pntd.0001430.g004
Immunoproteomic Approach in Leshmania infantum
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The life cycle and the clonal propagation of Leishmania represent
particular problems to obtain homogeneous populations of
parasites to use in comparative proteomic analyses. In addition,
it is difficult to purify amastigote-like stages from host tissues and,
in general, contamination with host proteins is an important
drawback to be overcome. Although axenic amastigotes display
many of the features of in vivo intracellular parasites, a constant
concern among researchers has been the extent to which axenic
amastigotes resemble the intracellular parasites [69,70].
The present study employed the protocol described by Doyle
et al. (1991) [35] to obtain amastigote-like stages of L. infantum.
Carvalho et al. (2002), using the same protocol in amastigote-like
stage, demonstrated the expression of the amastigote-specific A2
protein in L. chagasi and L. amazonensis [13], by applying Western
blot experiments using an A2-specific monoclonal antibody. In the
present work, A2 and two other amastigote-specific proteins –
ATP-dependent RNA helicase [58] and amastin [59] – were
detected in the immunoblots. The expression of these proteins by
the axenic amastigotes suggests that they are, at least in part,
comparable to tissue amastigotes and their gene expression, which
is in accordance with the approach used in the present study to
identify amastigote-specific antigens. Conversely, some proteins
that are known to be specific, or that are more highly expressed in
promastigotes, such as the flagellum transition zone component
and the phosphoglycan beta-1,3-galactosyltransferase, which is
linked to LPG synthesis, could only be detected in immunoblots of
promastigote antigenic extracts.
As expected, some of the proteins identified in the present work
have been previously associated with humoral responses in VL and
are candidate antigens for diagnosis. Curiously, Haspb, a protein
identified in promastigote extracts, presents a high homology,
together with a family of related hydrophilic, kinesin antigens of
Leishmania spp., which includes the K26 and K39. These antigens
were largely tested and used in serological diagnosis of VL,
although they have been reported to be more sensitive for the
diagnosis of symptomatic dogs [10,16,71].
The evolution from an asymptomatic to a symptomatic disease
is largely dependent on host immune responses. Immunopatho-
genesis of CVL has been associated with two major responses: a
Th1 immune response is linked to the control of infection and a
predominant, although not polarized, Th2 response responsible
for the development of a patent disease [72]. Here, several proteins
proved to be reactive when in contact with sera of asymptomatic
animals, a stage of infection in which dogs developing immune
responses able to control parasite replication. Although humoral
responses cannot be correlated directly with protection, IgG1 and
IgG2 responses are largely T-cell dependent. Moreover, IgG2
antibodies have been commonly associated with protective
immune responses and IFN-c production [73]. Therefore, parasite
antigens that react with antibodies from asymptomatic animals, in
addition to their potential as diagnostic antigens, may be
associated with protective responses and may well represent
potential vaccine candidates.
In addition, the use of pools of sera of both asymptomatic and
symptomatic VL dogs in the present study implies that no immune
response variations by individual animals to L. infantum antigens
Figure 5. Proteins of Leishmania infantum promastigotes
identified by an immunoproteomic approach. a) Sera samples
of dogs with VL. b) Name of the identified protein and species: Lmj, L.
major; Lbr, L. braziliensis; Li, L. infantum; Ld, L. donovani. c) Accession
numbers according to NCBI. d) Experimental expected and predicted
molecular weights (Mr, in KDa). e) Experimental expected and predicted
isoeletric points (pI).
doi:10.1371/journal.pntd.0001430.g005
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could be observed. Due to the high degree of variability found in
the humoral responses to different parasite antigens in CVL sera
[16], the results give rise to the possibility of obtaining new
recombinant antigens and analyzing their properties as tools for
the diagnosis of all forms of CVL.
Predominant proteins in the pI 4–7 2DE gels presented a
molecular mass range of between 15 and 50 kDa for promastigote
stage and of 25 to 70 kDa for the amastigote-like stage. These
results are in agreement with findings from Dea-Ayuela et al.
(2006) [74], who identified approximately 700 spots in promas-
tigote extracts, with molecular masses similar to those found in the
present study. By contrast, Brotherton et al. (2010) reported, for
the first time, several highly basic proteins in both amastigote and
promastigote protein extracts, which were enriched by coupling
fractionation by pI with free-flow electrophoresis in their
proteomic analysis of stage-specific expressions of L. infantum
[32]. Therefore, the selection of a pI 4–7 range may have limited
our analysis.
In addition, the presence of elongation factors; heat shock
proteins, such as HSP70, HSP83, and other chaperones; as well as
tubulin and other housekeeping proteins, among the most
abundantly detected in both antigenic extracts, were in good
agreement with other studies and present a reliable validation of
the immunoproteomic analysis performed herein [56,57]. Some
proteins detected in Leishmania extracts could be found in multiple
spots or as proteolytic fragments. In addition, protein degradation
cannot be completely discarded, although the protein extracts
were obtained in the presence of a cocktail of protease inhibitors.
However, this finding may also be associated with the presence of
isoforms or to the extensive post-translational modification and
processing of proteins, known to occur in Leishmania sp., and as
previously observed in other proteomic analyses [32].
The analysis of the three available Leishmania species genomes
(L. braziliensis, L. major, and L. infantum) revealed that they are highly
conserved at both nucleotide (less than 1% species-specific genes)
and aminoacid levels (77 to 92%), although it has been estimated
that Leishmania species have evolved from a common ancestor as
far as 15–50 million years ago [75]. Although Leishmania has a
digenetic life cycle with significant biochemical and morphological
alterations, it has been estimated that only 0.2% to 13.0% of these
genes show preferential stage-specific expression [76]. Therefore,
there is no consensus on the number of genes that are differentially
expressed in different stages, and discrepancies are likely due to the
design of the genomic and cDNA arrays used in different studies
[77]. Nevertheless, protein expression levels showed a weak
correlation with gene expression levels [29,75], which could be
linked to post-transcriptional events. In this context, proteomic
studies are crucial and may reveal how Leishmania uses this
conserved genetic background to generate protein variability, an
alternation of stages during its life cycle, and to cause rather
distinct diseases.
Tests based on serological techniques to diagnose human and
canine VL are facilitated by the strong humoral response that
accompanies the infection by viscerotropic Leishmania species [78].
Nonetheless, detection of asymptomatic dogs may be critical to
control epidemics and to avoid the spread of the disease among
dogs, as well as between dog and human populations [4,5,79].
However, total and soluble Leishmania antigen-based ELISA fails to
detect a great percentage of asymptomatic cases of the disease
[13,80]. Similar findings have also been reported for recombinant
antigens [16]. Therefore, there is still space to identify new
antigens capable, whether alone or in combination, of improving
the serological diagnosis of CVL. In this sense, the present study
represents a step forward in the proteomic analysis of Leishmania
Figure 6. Proteins of Leishmania infantum amastigotes-like
identified by an immunoproteomic approach. a) Sera samples
of dogs with VL. b) Name of the identified protein and species: Lmj, L.
major; Lbr, L. braziliensis; Li, L. infantum; Ld, L. donovani. c) Accession
numbers according to NCBI. d) Experimental expected and predicted
molecular weights (Mr, in KDa). e) Experimental expected and predicted
isoeletric points (pI).
doi:10.1371/journal.pntd.0001430.g006
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species since, in addition to known antigenic stage-specific
proteins, a high number of hypothetical proteins of L. infantum
were also identified. Altogether, these proteins warrant further
investigation in an attempt to potentially improve diagnosis. The
fact that antibodies present in the pools of sera of infected dogs
identified hypothetical proteins indicates that these proteins are
expressed during active infection. Therefore, the data obtained in
the present study represent not only a contribution toward the
future improvement of diagnostic tools and vaccines for CVL, but
also a step towards a better understanding of the biological role of
these proteins in L. infantum metabolism, virulence, and pathogen-
esis. Thus, additional studies are most certainly encouraged.
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